Fig. 1From: Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicinTreatment-free interval for patients treated with the combination of mitomycin C, cisplatin and doxorubicin and for women treated by the paclitaxel plus carboplatin doubletBack to article page